Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Jean M. Delabar; Julien Lagarde; Marta Fructuoso; Ammara Mohammad; Michel Bottlaender; Eric Doran; Ira Lott; Isabelle Rivals; Frederic A. Schmitt; Elizabeth Head; Marie Sarazin; Marie Claude Potier

doi:10.1038/s41398-023-02419-0

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Jean M. Delabar, Julien Lagarde, Marta Fructuoso, Ammara Mohammad, Michel Bottlaender, Eric Doran, Ira Lott, Isabelle Rivals, Frederic A. Schmitt, Elizabeth Head, Marie Sarazin, Marie Claude Potier

Research output: Contribution to journal › Article › peer-review

Abstract

Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.

Original language	English
Article number	111
Journal	Translational Psychiatry
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41398-023-02419-0
State	Published - Dec 2023

Bibliographical note

Funding Information:
This study was supported by INSERM in collaboration with Institut du Cerveau et de la Moelle Epinière (ICM), Institut Hospitalo Universitaire. Cerveau et de la Moelle Epiniere (ICM), Institut Hospitalo-Universitaire-A ICM, and was supported with funding from the Investissement d’Avenir (ANR-10-AIHU-06). and by a grant from Lejeune foundation

Publisher Copyright:
© 2023, The Author(s).

ASJC Scopus subject areas

Psychiatry and Mental health
Cellular and Molecular Neuroscience
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41398-023-02419-0

Cite this

@article{f6c8b55293b544e68dc082e88e2273e2,

title = "Increased plasma DYRK1A with aging may protect against neurodegenerative diseases",

abstract = "Early markers are needed for more effective prevention of Alzheimer{\textquoteright}s disease. We previously showed that individuals with Alzheimer{\textquoteright}s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer{\textquoteright}s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.",

author = "Delabar, {Jean M.} and Julien Lagarde and Marta Fructuoso and Ammara Mohammad and Michel Bottlaender and Eric Doran and Ira Lott and Isabelle Rivals and Schmitt, {Frederic A.} and Elizabeth Head and Marie Sarazin and Potier, {Marie Claude}",

note = "Funding Information: This study was supported by INSERM in collaboration with Institut du Cerveau et de la Moelle Epini{\`e}re (ICM), Institut Hospitalo Universitaire. Cerveau et de la Moelle Epiniere (ICM), Institut Hospitalo-Universitaire-A ICM, and was supported with funding from the Investissement d{\textquoteright}Avenir (ANR-10-AIHU-06). and by a grant from Lejeune foundation Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41398-023-02419-0",

language = "English",

volume = "13",

number = "1",

}

TY - JOUR

T1 - Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

AU - Delabar, Jean M.

AU - Lagarde, Julien

AU - Fructuoso, Marta

AU - Mohammad, Ammara

AU - Bottlaender, Michel

AU - Doran, Eric

AU - Lott, Ira

AU - Rivals, Isabelle

AU - Schmitt, Frederic A.

AU - Head, Elizabeth

AU - Sarazin, Marie

AU - Potier, Marie Claude

N1 - Funding Information: This study was supported by INSERM in collaboration with Institut du Cerveau et de la Moelle Epinière (ICM), Institut Hospitalo Universitaire. Cerveau et de la Moelle Epiniere (ICM), Institut Hospitalo-Universitaire-A ICM, and was supported with funding from the Investissement d’Avenir (ANR-10-AIHU-06). and by a grant from Lejeune foundation Publisher Copyright: © 2023, The Author(s).

PY - 2023/12

Y1 - 2023/12

N2 - Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.

AB - Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.

UR - http://www.scopus.com/inward/record.url?scp=85151792238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151792238&partnerID=8YFLogxK

U2 - 10.1038/s41398-023-02419-0

DO - 10.1038/s41398-023-02419-0

M3 - Article

C2 - 37015911

AN - SCOPUS:85151792238

SN - 2158-3188

VL - 13

JO - Translational Psychiatry

JF - Translational Psychiatry

IS - 1

M1 - 111

ER -

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this